Zhu J, Jiang R, Zhang H, Fang Z, Zhou H, Wei Q
Discov Oncol. 2024; 15(1):843.
PMID: 39729236
PMC: 11680531.
DOI: 10.1007/s12672-024-01705-7.
Delgado-Sequera A, Perez-Revuelta J, Caballero-Garcia A, Duran-Ruiz M, Romero-Lopez-Alberca C, Garcia-Mompo C
Mol Med. 2024; 30(1):271.
PMID: 39716063
PMC: 11667855.
DOI: 10.1186/s10020-024-01039-8.
Dong Y, Zhang Z, Luan S, Zheng M, Wang Z, Chen Y
J Immunother Cancer. 2024; 12(10).
PMID: 39357981
PMC: 11448212.
DOI: 10.1136/jitc-2024-009710.
Rodrigues A, Chernikova S, Wang Y, Trinh T, Solow-Cordero D, Alexandrova L
J Neurooncol. 2024; 168(1):125-138.
PMID: 38563850
PMC: 11093727.
DOI: 10.1007/s11060-024-04654-x.
Saltalamacchia G, Torrisi R, De Sanctis R, Masci G, Miggiano C, Gaudio M
Biomedicines. 2024; 12(3).
PMID: 38540113
PMC: 10967814.
DOI: 10.3390/biomedicines12030500.
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L, Lu Y, Liu W, Wang S, Wang L, Zheng P
Exp Hematol Oncol. 2024; 13(1):26.
PMID: 38429828
PMC: 10908151.
DOI: 10.1186/s40164-024-00493-8.
Alendronate-Grafted Nanoemulsions for Bone-Targeted Vincristine Delivery: Preliminary Studies on Cell and Animal Models.
Stoppa I, Dianzani C, Clemente N, Bozza A, Bordano V, Garelli S
Biomolecules. 2024; 14(2).
PMID: 38397475
PMC: 10886946.
DOI: 10.3390/biom14020238.
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions.
Kumari S, Raj S, Babu M, Bhatti G, Bhatti J
Arch Pharm Res. 2023; 47(1):40-65.
PMID: 38153656
DOI: 10.1007/s12272-023-01479-6.
Cytotoxicity of poly-guanidine in medulloblastoma cell lines.
Gallo-Oller G, Diaz De Stahl T, Alaiya A, Nilsson S, Holmberg A, Marquez-Mendez M
Invest New Drugs. 2023; 41(5):688-698.
PMID: 37556022
PMC: 10560188.
DOI: 10.1007/s10637-023-01386-z.
Green-Based Approach to Synthesize Silver Nanoparticles Using the Fungal Endophyte and Their Antimicrobial, Antioxidant, and Anticancer Potential.
Gupta P, Rai N, Verma A, Saikia D, Singh S, Kumar R
ACS Omega. 2022; 7(50):46653-46673.
PMID: 36570288
PMC: 9774420.
DOI: 10.1021/acsomega.2c05605.
Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells.
Ovejero-Sanchez M, Asensio-Juarez G, Gonzalez M, Puebla P, Vicente-Manzanares M, Pelaez R
Int J Mol Sci. 2022; 23(21).
PMID: 36361809
PMC: 9657298.
DOI: 10.3390/ijms232113019.
Time-Series Clustering of Single-Cell Trajectories in Collective Cell Migration.
Xin Z, Kajita M, Deguchi K, Suye S, Fujita S
Cancers (Basel). 2022; 14(19).
PMID: 36230509
PMC: 9559181.
DOI: 10.3390/cancers14194587.
Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
Fu Z, Li S, Han S, Shi C, Zhang Y
Signal Transduct Target Ther. 2022; 7(1):93.
PMID: 35318309
PMC: 8941077.
DOI: 10.1038/s41392-022-00947-7.
Nuclear Transport Factor 2 (NTF2) suppresses WM983B metastatic melanoma by modifying cell migration, metastasis, and gene expression.
Vukovic L, Chen P, Mishra S, White K, Gigley J, Levy D
Sci Rep. 2021; 11(1):23586.
PMID: 34880267
PMC: 8654834.
DOI: 10.1038/s41598-021-02803-0.
Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles.
Wordeman L, Vicente J
Cancers (Basel). 2021; 13(22).
PMID: 34830812
PMC: 8616087.
DOI: 10.3390/cancers13225650.
HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins.
Jiang X, Lu X, Gentles A, Zhao D, Wander S, Zhang Y
Blood Adv. 2021; 5(23):5072-5085.
PMID: 34543391
PMC: 9153012.
DOI: 10.1182/bloodadvances.2021004304.
Tracking cell migration by cellular force footprint recorded with a mechano-optical biosensor.
Tu Y, Wang X
Biosens Bioelectron. 2021; 193:113533.
PMID: 34343934
PMC: 8492532.
DOI: 10.1016/j.bios.2021.113533.
Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis.
Datta A, Deng S, Gopal V, Yap K, Halim C, Lye M
Cancers (Basel). 2021; 13(8).
PMID: 33919917
PMC: 8070945.
DOI: 10.3390/cancers13081882.
The Frequent Sampling of Wound Scratch Assay Reveals the "Opportunity" Window for Quantitative Evaluation of Cell Motility-Impeding Drugs.
Kauanova S, Urazbayev A, Vorobjev I
Front Cell Dev Biol. 2021; 9:640972.
PMID: 33777948
PMC: 7991799.
DOI: 10.3389/fcell.2021.640972.
MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain.
Wang H, Jiang X, Cheng Y, Ren H, Hu Y, Zhang Y
Cancer Sci. 2021; 112(6):2210-2222.
PMID: 33754417
PMC: 8177791.
DOI: 10.1111/cas.14900.